Cytek Biosciences Inc (CTKB)

Pretax margin

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022
Earnings before tax but after interest (EBT) (ttm)	US$ in thousands	-15,709	-15,706	-9,671	-4,477	1,260	-2,410	-2,185	2,483
Revenue (ttm)	US$ in thousands	193,014	183,117	175,594	166,060	164,036	155,086	148,985	139,234
Pretax margin		-8.14%	-8.58%	-5.51%	-2.70%	0.77%	-1.55%	-1.47%	1.78%

December 31, 2023 calculation

Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $-15,709K ÷ $193,014K
= -8.14%

The pretax margin of Cytek Biosciences Inc has shown a declining trend over the past eight quarters. From a positive 1.78% in the first quarter of 2022, the pretax margin gradually decreased to negative figures, reaching a low of -8.58% in the second quarter of 2023. This negative trend indicates that the company's profitability before accounting for taxes has been deteriorating. It is essential for the company to closely monitor and evaluate its cost structure, revenue generation, and operational efficiency to improve its pretax margin and overall financial performance in the future.